604 related articles for article (PubMed ID: 18495078)
1. Bluetongue virus: virology, pathogenesis and immunity.
Schwartz-Cornil I; Mertens PP; Contreras V; Hemati B; Pascale F; Bréard E; Mellor PS; MacLachlan NJ; Zientara S
Vet Res; 2008; 39(5):46. PubMed ID: 18495078
[TBL] [Abstract][Full Text] [Related]
2. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
[TBL] [Abstract][Full Text] [Related]
3. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
[TBL] [Abstract][Full Text] [Related]
4. Vaccines against bluetongue in Europe.
Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
[TBL] [Abstract][Full Text] [Related]
5. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
[TBL] [Abstract][Full Text] [Related]
6. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
[TBL] [Abstract][Full Text] [Related]
7. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
[TBL] [Abstract][Full Text] [Related]
8. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants.
Perrin A; Albina E; Bréard E; Sailleau C; Promé S; Grillet C; Kwiatek O; Russo P; Thiéry R; Zientara S; Cêtre-Sossah C
Vaccine; 2007 Sep; 25(37-38):6774-83. PubMed ID: 17669563
[TBL] [Abstract][Full Text] [Related]
9. Bluetongue vaccines: the past, present and future.
Bhanuprakash V; Indrani BK; Hosamani M; Balamurugan V; Singh RK
Expert Rev Vaccines; 2009 Feb; 8(2):191-204. PubMed ID: 19196199
[TBL] [Abstract][Full Text] [Related]
10. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
[TBL] [Abstract][Full Text] [Related]
11. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
Kochinger S; Renevey N; Hofmann MA; Zimmer G
Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective.
McVey DS; MacLachlan NJ
Vector Borne Zoonotic Dis; 2015 Jun; 15(6):385-96. PubMed ID: 26086559
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep.
Umeshappa CS; Singh KP; Pandey AB; Singh RP; Nanjundappa RH
Vaccine; 2010 Mar; 28(13):2522-31. PubMed ID: 20117268
[TBL] [Abstract][Full Text] [Related]
14. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
Feenstra F; Pap JS; van Rijn PA
Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
[TBL] [Abstract][Full Text] [Related]
15. Immunologic response of sheep to inactivated and virulent bluetongue virus.
Stott JL; Barber TL; Osburn BI
Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
[TBL] [Abstract][Full Text] [Related]
16. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
[TBL] [Abstract][Full Text] [Related]
17. Differentiation between field and vaccine strain of bluetongue virus serotype 16.
Monaco F; Cammà C; Serini S; Savini G
Vet Microbiol; 2006 Aug; 116(1-3):45-52. PubMed ID: 16713688
[TBL] [Abstract][Full Text] [Related]
18. Nature and duration of protective immunity to bluetongue virus infection.
Roy P
Dev Biol (Basel); 2003; 114():169-83. PubMed ID: 14677687
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cross-protection of bluetongue virus serotype 4 with other serotypes in sheep.
Zulu GB; Venter EH
J S Afr Vet Assoc; 2014 Oct; 85(1):1041. PubMed ID: 25686101
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vaccines against bluetongue virus.
Calvo-Pinilla E; Castillo-Olivares J; Jabbar T; Ortego J; de la Poza F; Marín-López A
Virus Res; 2014 Mar; 182():78-86. PubMed ID: 24287057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
